FDA approves oral solution Cuvposa for chronic drooling in children

07/29/2010 | Modern Medicine

The FDA approved Shionogi Pharma's Cuvposa, a flavored liquid form of glycopyrrolate, for the treatment of chronic drooling in patients ages 3 to 16 with neuromuscular disorders. Glycopyrrolate has long been approved for patients with peptic ulcers and to reduce salivation among those under anesthesia.

View Full Article in:

Modern Medicine

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ